Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Total Liabilities
Everything the company owes to creditors and other parties.
Nuvation Bio Inc.NYSE: NUVB
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 78.9% from a year ago
Total liabilities stood at $490.64M at the end of Q2 FY2026, up 78.9% from a year earlier and up 68.8% from the prior quarter. Over 3 fiscal years it compounded at +156.8% a year.
Context
- Total liabilities amounted to 65.9% of total assets at the end of Q2 FY2026, up 23.5 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +78.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 289.11M USD
- Year-over-year change
- +276.3%
- 4-year CAGR
- +76.0%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 289.11M | +276.3% |
| FY2024 | 2024-12-31 | 76.84M | +369.6% |
| FY2023 | 2023-12-31 | 16.36M | -4.1% |
| FY2022 | 2022-12-31 | 17.07M | -43.4% |
| FY2021 | 2021-12-31 | 30.15M | — |
Total Liabilities vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's Jun 2026 total liabilities of $490.64M is the 2nd highest of the 11 companies compared; the peer median is $149.15M.
- Its year-over-year change of +78.9% is the 4th highest of 11, against a peer median of +28.7%.
- Total liabilities amounts to 65.9% of total assets for NUVB, versus a peer median of 21.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $629.36M | +10.1% | +39.8% | 80.8% | |
| Jun 2026 | $490.64M | +78.9% | +156.8% | 65.9% | |
| Sep 2026 | $437.36M | +11.6% | +8.2% | 29.2% | |
| Jun 2026 | $435.14M | +548.0% | +64.2% | 39.7% | |
| Jun 2026 | $177.4M | +6.1% | +37.5% | 22.4% | |
| Mar 2026 | $150.96M | +7.8% | +10.5% | 20.6% | |
| Sep 2026 | $147.35M | +493.7% | +14.2% | 8.3% | |
| Jun 2026 | $125.23M | +13.6% | +33.7% | 23.5% | |
| Mar 2026 | $86.69M | +126.3% | +5.4% | 8.4% | |
| Sep 2026 | $72.06M | +43.9% | +28.1% | 10.0% | |
| Jun 2026 | $71.01M | +60.1% | -31.8% | 5.0% | |
| Peer median (excluding NUVB) | $149.15M | +28.7% | +21.2% | 21.5% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 132.42M | 101.1M | 42.65M | 35.72M | 164.09M |
| Short-term Investments | 632.97M | 559.92M | 568.56M | 466.97M | 365.13M |
| Net Receivables | 3.04M | 2.49M | 3.7M | 16.29M | 19.36M |
| Inventory | 0 | 0 | 0 | 0 | 11.41M |
| Other Current Assets | 0 | 3.82M | 1.52M | 7.27M | 11.54M |
| Total Current Assets | 772.07M | 667.32M | 616.43M | 526.26M | 571.52M |
| Property, Plant & Equipment (Net) | 3.66M | 4.69M | 4.32M | 2.99M | 4.48M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 4.62M | 11.21M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 421K | 138K | 728K | 6.76M | 7.61M |
| Total Non-current Assets | 4.08M | 4.82M | 5.05M | 14.37M | 23.3M |
| Total Assets | 776.15M | 672.14M | 621.48M | 540.63M | 594.82M |
| Account Payables | 3.93M | 2.14M | 2.21M | 6.35M | 9.48M |
| Short-term Debt | 0 | 0 | 0 | 6.28M | 7.6M |
| Tax Payables | 402K | 112K | 144K | 679K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 11.12M | 0 |
| Other Current Liabilities | 6.17M | 3.99M | 4.35M | 14.82M | 65.15M |
| Total Current Liabilities | 16.93M | 13.16M | 13.97M | 58.24M | 82.23M |
| Long-term Debt | 0 | 0 | 0 | 0 | 2.54M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 15.57M | 145.82M |
| Other Non-current Liabilities | 11.04M | 850K | 353K | 2.05M | 58.51M |
| Total Non-current Liabilities | 13.23M | 3.9M | 2.39M | 18.59M | 206.88M |
| Total Liabilities | 30.15M | 17.07M | 16.36M | 76.84M | 289.11M |
| Common Stock | 909.99M | 927.6M | 947.75M | 1.37B | 1.42B |
| Retained Earnings | (162.8M) | (267M) | (342.8M) | (910.74M) | (1.12B) |
| Accumulated OCI | (1.19M) | (5.53M) | 181K | 573K | (187K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 746M | 655.08M | 605.12M | 463.79M | 305.72M |
| Total Debt | 3.06M | 4.26M | 4.01M | 8.92M | 10.15M |
| Net Debt | (129.37M) | (96.84M) | (38.64M) | (26.81M) | (153.94M) |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.